Novartis Presents Published Phase III REPLENISH Data In New England Journal Of Medicine Showing Cosentyx Achieves Statistically Significant Sustained Remission And Steroid Sparing In Polymyalgia Rheumatica With No New Safety Signals

뉴스 본문을 불러오고 있어요.

Novartis Presents Published Phase III REPLENISH Data In New England Journal Of Medicine Showing Cosentyx Achieves Statistically Significant Sustained Remission And Steroid Sparing In Polymyalgia Rheumatica With No New Safety Signals | 웨이프 WAPE

Novartis Presents Published Phase III REPLENISH Data In New England Journal Of Medicine Showing Cosentyx Achieves Statistically Significant Sustained Remission And Steroid Sparing In Polymyalgia Rheumatica With No New Safety Signals

기사 요약

관련 종목

댓글 —